Sesen Bio, Inc.
SESN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 0.01 | -0.00 | -0.03 |
| FCF Yield | -22.47% | -38.54% | -232.88% | -109.75% |
| EV / EBITDA | 0.00 | 0.00 | 2.53 | 0.00 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 404.18% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.04 | 0.60 | 1.09 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -68.08% | -33.89% |
| Free Cash Flow Growth | 41.35% | 83.42% | -111.52% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -3.66 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | -105.45 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |